1. Academic Validation
  2. Osteogenic effect of an adiponectin-derived short peptide that rebalances bone remodeling: a potential disease-modifying approach for postmenopausal osteoporosis therapy

Osteogenic effect of an adiponectin-derived short peptide that rebalances bone remodeling: a potential disease-modifying approach for postmenopausal osteoporosis therapy

  • Arch Pharm Res. 2024 Jul 29. doi: 10.1007/s12272-024-01509-x.
Swati Rajput 1 2 Chirag Kulkarni 1 2 Shivani Sharma 1 2 Manendra Singh Tomar 3 Shamima Khatoon 4 Arvind Gupta 5 Sabyasachi Sanyal 4 Ashutosh Shrivastava 3 Jimut Kanti Ghosh 2 5 Naibedya Chattopadhyay 6 7
Affiliations

Affiliations

  • 1 Division of Endocrinology and Centre for Research in Anabolic Skeletal Targets in Health and Illness (ASTHI), CSIR-Central Drug Research Institute, Sector 10, Jankipuram Extension, Sitapur Road, Lucknow, 226031, India.
  • 2 Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India.
  • 3 Centre for Advance Research, Faculty of Medicine, King George's Medical University, Lucknow, India.
  • 4 Division of Biochemistry and Structural Biology, CSIR-Central Drug Research Institute, Sector 10, Jankipuram Extension, Sitapur Road, Lucknow, 226031, India.
  • 5 Molecular and Structural Biology Division, CSIR-Central Drug Research Institute, Sector 10, Jankipuram Extension, Sitapur Road, Lucknow, 226031, India.
  • 6 Division of Endocrinology and Centre for Research in Anabolic Skeletal Targets in Health and Illness (ASTHI), CSIR-Central Drug Research Institute, Sector 10, Jankipuram Extension, Sitapur Road, Lucknow, 226031, India. n_chattopadhyay@cdri.res.in.
  • 7 Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India. n_chattopadhyay@cdri.res.in.
Abstract

Adiponectin, an adipokine, regulates metabolic processes, including glucose flux, lipid breakdown, and Insulin response, by activating Adiponectin receptors 1 and 2 (AdipoR1 and AdipoR2). We have previously shown that globular Adiponectin (gAd), an endogenous form of Adiponectin, has osteoanabolic and anti-catabolic effects in rodent models of postmenopausal osteopenia. Moreover, we reported the identification of a 13-mer peptide (ADP-1) from the collagen domain of Adiponectin, which exhibited significant adiponectin-mimetic properties. Since the clinical development of gAd is constrained by its large size, here, we investigated the osteogenic property of ADP-1. ADP-1 induced osteoblast differentiation more potently than gAd. ADP-1 elicited osteoblast differentiation through two downstream pathways that involved the participation of Adiponectin receptors. Firstly, it enhanced mitochondrial biogenesis and OxPhos, leading to osteoblast differentiation. Secondly, it activated the Akt-glycogen synthase kinase 3β-Wnt pathway, thereby increasing osteoblast differentiation. Additionally, ADP-1 suppressed the production of receptor-activator of nuclear kappa B ligand from osteoblasts, enabling it to act as a dual-action molecule (suppressing osteoclast function besides promoting osteoblast function). In osteopenic ovariectomized rats, ADP-1 increased bone mass and strength and improved trabecular integrity by stimulating bone formation and inhibiting bone resorption. Furthermore, by increasing ATP-producing intermediates within the tricarboxylic acid cycle in bones, ADP-1 likely fueled osteoblast function. Given its dual-action mechanism and high potency, ADP-1 offers a unique opportunity to address the unmet clinical need to reset the aberrant bone remodeling in osteoporosis to normalcy, potentially offering a disease-modifying impact.

Keywords

Bone mass; Bone remodeling; Bone resorption; Bone strength; Mitochondrial biogenesis; Postmenopausal osteoporosis.

Figures
Products